Literature DB >> 20113679

Radioembolization of liver tumors with yttrium-90 microspheres.

Hojjat Ahmadzadehfar1, Hans-Jürgen Biersack, Samer Ezziddin.   

Abstract

Radioembolization (RE), also termed selective internal radiation therapy (SIRT), has been gradually introduced to the clinical arsenal of cytoreductive modalities in recent years. There is growing evidence for efficiency in liver tumors of various entities, with the most prominent ones being hepatocellular carcinoma, colorectal cancer, and neuroendocrine tumors. Hepatic metastases of numerous other tumor entities including breast cancer, cholangiocarcinoma, and pancreatic cancer are treatment-sensitive, even when being refractory to other treatment modalities such as bland-embolization, regional, or systemic chemotherapy. The antitumor effect of SIRT is related to radiation rather than embolization, with extraordinary high local radiation doses obtained selectively at the site of viable tumor and little affection of the surrounding normal liver tissue. Morphologic changes after RE may pose difficulties for interpretation in conventional restaging with regard to tumor viability and true response to treatment. Therefore, functional imaging, that is, metabolic imaging with (18)F fluorodeoxyglucose positron emission tomography (computed tomography) in the majority of treated tumors, is regarded the gold standard in this respect and should be included for pre- and post-SIRT assessment. To prevent serious toxicity to be associated with the potent antitumor efficacy, meticulous pretreatment evaluation is of particular importance. Improvements in predicting dosimetry will help optimize treatment and patient selection. Nuclear medicine procedures are essential for planning, performing, and monitoring of RE. However, the interdisciplinary aspect of patient management has to be emphasized for this particular treatment form. As SIRT is moving forward from the salvage setting indication to the use in earlier stages of hepatic tumor disease and with the advent of new treatment protocols and targeted therapies, embedding SIRT into a multidisciplinary approach will become even more important. This article focuses on procedural and technical aspects for selection, preparation, and performance of treatment as well as post-therapeutic monitoring and response assessment.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20113679     DOI: 10.1053/j.semnuclmed.2009.11.001

Source DB:  PubMed          Journal:  Semin Nucl Med        ISSN: 0001-2998            Impact factor:   4.446


  43 in total

1.  Is prophylactic embolization of the hepatic falciform artery needed before radioembolization in patients with 99mTc-MAA accumulation in the anterior abdominal wall?

Authors:  Hojjat Ahmadzadehfar; Markus Möhlenbruch; Amir Sabet; Carsten Meyer; Marianne Muckle; Torjan Haslerud; Kai Wilhelm; Hans Heinz Schild; Hans Jürgen Biersack; Samer Ezziddin
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-04-15       Impact factor: 9.236

2.  Pre-therapeutic factors for predicting survival after radioembolization: a single-center experience in 389 patients.

Authors:  K J Paprottka; F Schoeppe; M Ingrisch; J Rübenthaler; N N Sommer; E De Toni; H Ilhan; M Zacherl; A Todica; P M Paprottka
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-02-14       Impact factor: 9.236

3.  Diffusion-weighted magnetic resonance imaging predicts survival in patients with liver-predominant metastatic colorectal cancer shortly after selective internal radiation therapy.

Authors:  Frederic Carsten Schmeel; Birgit Simon; Amir Sabet; Julian Alexander Luetkens; Frank Träber; Leonard Christopher Schmeel; Samer Ezziddin; Hans Heinz Schild; Dariusch Reza Hadizadeh
Journal:  Eur Radiol       Date:  2016-06-07       Impact factor: 5.315

4.  Robust evidence for long-term survival with 90Y radioembolization in chemorefractory liver-predominant metastatic colorectal cancer.

Authors:  T F Jakobs; K J Paprottka; F Raeßler; F Strobl; S Lehner; H Ilhan; C G Trumm; W P Fendler; W Sommer; P M Paprottka
Journal:  Eur Radiol       Date:  2016-04-08       Impact factor: 5.315

Review 5.  Cholangiocarcinoma--controversies and challenges.

Authors:  Tushar Patel
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-04       Impact factor: 46.802

Review 6.  Yttrium-90 Radioembolization Dosimetry: What Trainees Need to Know.

Authors:  Alexander Villalobos; Mohamed M Soliman; Bill S Majdalany; David M Schuster; James Galt; Zachary L Bercu; Nima Kokabi
Journal:  Semin Intervent Radiol       Date:  2020-12-11       Impact factor: 1.513

7.  Prognostic value of pretreatment diffusion-weighted magnetic resonance imaging for outcome prediction of colorectal cancer liver metastases undergoing 90Y-microsphere radioembolization.

Authors:  Frederic Carsten Schmeel; Birgit Simon; Julian Alexander Luetkens; Frank Träber; Carsten Meyer; Leonard Christopher Schmeel; Amir Sabet; Samer Ezziddin; Hans Heinz Schild; Dariusch Reza Hadizadeh
Journal:  J Cancer Res Clin Oncol       Date:  2017-03-19       Impact factor: 4.553

8.  Improving quality of life in patients with pancreatic neuroendocrine tumor following peptide receptor radionuclide therapy assessed by EORTC QLQ-C30.

Authors:  Milka Marinova; Martin Mücke; Lukas Mahlberg; Markus Essler; Henning Cuhls; Lukas Radbruch; Rupert Conrad; Hojjat Ahmadzadehfar
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-09-01       Impact factor: 9.236

Review 9.  Radioembolization with Yttrium-90 microspheres in hepatocellular carcinoma: Role and perspectives.

Authors:  Cristina Mosconi; Alberta Cappelli; Cinzia Pettinato; Rita Golfieri
Journal:  World J Hepatol       Date:  2015-04-18

10.  Hepatic volume changes induced by radioembolization with 90Y resin microspheres. A single-centre study.

Authors:  Hojjat Ahmadzadehfar; Carsten Meyer; Samer Ezziddin; Amir Sabet; Anja Hoff-Meyer; Marianne Muckle; Timur Logvinski; Hans Heinz Schild; Hans Jürgen Biersack; Kai Wilhelm
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-10-13       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.